Brief: Atara Biotherapeutics Presents Preclinical Data On Ata3219, A Therapy For The Treatment Of B-Cell Driven Autoimmune Diseases
29/05/2024 22:05
May 29 (Reuters) - Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS PRESENTS PRECLINICAL DATA ON
ATA3219, AN
ALLOGENEIC CD19-TARGETED CAR T THERAPY FOR THE TREATMENT OF
B-CELL DRIVEN AUTOIMMUNE DISEASES, AT THE ISCT 2024 ANNUAL
MEETING
* ATARA BIOTHERAPEUTICS - PRECLINICAL RESULTS SUPPORT
ADVANCING
ATA3219 TOWARDS CLINICAL EVALUATION IN PATIENTS WITH B-CELL
DRIVEN AUTOIMMUNE DISEASES
Source text for Eikon: ID:nBw5lydF6a
Further company coverage: ATRA.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing